<DOC>
	<DOCNO>NCT03053284</DOCNO>
	<brief_summary>This small control pilot study assess effect subcutaneous pasireotide prevent hypoglycemia due hyperinsulinism , include congenital hyperinsulinism insulinoma .</brief_summary>
	<brief_title>Pasireotide Hyperinsulinemic Hypoglycemia</brief_title>
	<detailed_description>Pasireotide somatostatin analog affinity several somatostatin receptor include pancreatic beta cell ; activate receptor affect secretion glucagon insulin . Pasireotide also know decrease glucagon-like peptide 1 ( GLP-1 ) gastric inhibitory polypeptide ( GIP ) secretion . Hyperglycemia well-documented adverse effect pasireotide approve indication treatment Cushing 's disease acromegaly . In light , investigator hypothesize pasireotide may effective therapy hypoglycemia due hyperinsulinism . Therefore small control pilot study assess effect subcutaneous ( s.c. ) pasireotide prevent hypoglycemia due hyperinsulinism 7 hour observation fast feed state propose .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Congenital Hyperinsulinism</mesh_term>
	<mesh_term>Insulinoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient age 18 70 year old 2 . Patients hyperinsulinemic hypoglycemia due either congenital hyperinsulinemic hypoglycemia insulinoma , determine endocrinologist 3 . If prior diagnosis either insulinoma congenital hyperinsulinemic hypoglycemia endocrinologist , participant must meet following criterion : A history symptom hypoglycemia , ( without blood glucose &lt; 50mg/dL time symptom ) Improvement symptom ingestion carbohydrate At least one document blood glucose &lt; 50mg/dL concomitant insulin &gt; 3 mmol/L cpeptide &gt; 0.2nmol/L , negative sulfonylurea screen At least 1 episode glucose &lt; 50mg/dL last year 4 . Written inform consent obtain prior treatment consistent local regulatory requirement 5 . No evidence significant liver disease : Serum total bilirubin &lt; 2 x ULN INR &lt; 1.3 unless anticoagulation ALT AST &lt; 2 x ULN Alkaline phosphatase &lt; 2.5 x ULN 6 . Patients receive antihypoglycemic treatment eligible 7 . Patients treatment na√Øve , previously , currently , treat antihypoglycemic therapy also eligible 8 . Patients insulinoma operative candidate eligible surgery emergently need , study participation would delay time surgical intervention Exclusion criterion : 1 . Age &lt; 18 , age &gt; 70 ( insulinoma congenital hyperinsulinism ) 2 . Known hypersensitivity somatostatin analogues 3 . Diabetic patient poor glycemic control evidence HbA1c &gt; 8 % 4 . Patients hypothyroid adequate replacement therapy 5 . Patients symptomatic cholelithiasis acute chronic pancreatitis 6 . QTcF screen &gt; 450 msec male QTcF &gt; 460 msec female 7 . Hypokalaemia , hypomagnesaemia , family history long QT syndrome concomitant medication know risk Torsades de pointes ( TdP ) 8 . Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , clinically significant bradycardia , advanced heart block , history acute MI le one year prior study entry clinically significant impairment cardiovascular function 9 . Severe nonmalignant medical illness may jeopardize treatment single dose pasireotide 10 . History another primary malignancy , exception locally excise nonmelanoma skin cancer carcinoma situ uterine cervix unless evidence disease last year 11 . Patients serum creatinine &gt; 2.0 X ULN 12 . Patients WBC &lt; 3 X 109/L ; Hb 90 % &lt; LLN ; PLT &lt; 100 X 109/L 13 . Patients presence active suspect acute chronic uncontrolled infection 14 . Patients undergone major surgery/surgical therapy cause within 4 week prior screen 15 . History unexplained syncope family history idiopathic sudden death 16 . Sexually active male unless use condom intercourse take drug 3 month follow last dose pasireotide father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . 17 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test 18 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 30 day follow last dose pasireotide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>